A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE)
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2017
Price : $35 *
At a glance
- Drugs Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms REGAIN
- Sponsors Janssen; Janssen Biotech
- 24 Nov 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Oct 2014 Planned End Date changed from 1 Sep 2016 to 1 Jan 2015 as reported by ClinicalTrials.gov record.